

Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy

*This measure is to be reported for all patients aged 18 years and older with MDS — a minimum of **once** per reporting period.*

Measure description

Percentage of patients aged 18 years and older with a diagnosis of MDS who are receiving erythropoietin therapy with documentation of iron stores prior to initiating erythropoietin therapy

What will you need to report for each patient with MDS for this measure?

If you select this measure for reporting, you will report:

- Whether or not the patient is receiving erythropoietin therapy

If the patient is receiving erythropoietin therapy, you will then need to report:

- Whether or not you documented iron stores prior to initiating therapy (regardless of when the documentation of iron stores occurred)

What if this process or outcome of care is not appropriate for your patient?

There may be times when it is not appropriate to document iron stores prior to initiating erythropoietin therapy, due to:

- System reasons (eg, resources to perform the services not available, insurance coverage/payer-related limitations, other reason attributable to health care delivery system)

In these cases, you will need to indicate that the system reason applies, specify the reason on the worksheet and in the medical chart. The office/billing staff will then report a code with a modifier that represents these valid reasons (also called exclusions).

Myelodysplastic Syndrome (MDS)

Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy

PQRI Data Collection Sheet

Patient's Name	Practice Medical Record Number (MRN)	Birth Date (mm/dd/yyyy) / /	Gender <input type="checkbox"/> Male <input type="checkbox"/> Female
National Provider Identifier (NPI)		Date of Service	

Clinical Information

Billing Information

Step 1 Is patient eligible for this measure?			
	Yes	No	Code Required on Claim Form
Patient is aged 18 years and older.	<input type="checkbox"/>	<input type="checkbox"/>	Verify date of birth on claim form.
Patient has a diagnosis of myelodysplastic syndrome (MDS).	<input type="checkbox"/>	<input type="checkbox"/>	Refer to coding specifications document for list of applicable codes.
There is a CPT E/M Service Code for this visit.	<input type="checkbox"/>	<input type="checkbox"/>	
If No is checked for any of the above, STOP. Do not report a CPT category II code.			
Step 2 Does patient also have the other requirements for this measure?			
	Yes	No	Code to be Reported on Line 24D of Paper Claim Form (or Service Line 24 of Electronic Claim Form)
Is patient receiving erythropoietin therapy ¹ ?	<input type="checkbox"/>	<input type="checkbox"/>	If No , report only 4095F and STOP. If Yes , report 4090F and proceed to Step 3.
Step 3 Does patient meet or have an acceptable reason for not meeting the measure?			
Iron Stores Prior to Initiating Erythropoietin Therapy	Yes	No	Code to be Reported on Line 24D of Paper Claim Form, if Yes (or Service Line 24 of Electronic Claim Form)
Documented ²	<input type="checkbox"/>	<input type="checkbox"/>	3160F
Not documented for the following reason: • System (eg, resources not available, other reason attributable to health care delivery system)	<input type="checkbox"/>	<input type="checkbox"/>	3160F-3P
Document reason here and in medical chart. _____ _____			If No is checked for all of the above, report 3160F-8P (Iron stores prior to initiating erythropoietin therapy not documented, reason not otherwise specified.)

¹For the purpose of this measure erythropoietin therapy includes the following medications: epoetin and darbepoetin.

²Documentation of iron stores includes either: Bone marrow examination including iron stain OR Serum iron measurement by ferritin or serum iron and TIBC.

Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy

Coding Specifications

Codes required to document patient has MDS and a visit occurred:

An ICD-9 diagnosis code for MDS and a CPT E/M service code are required to identify patients to be included in this measure.

MDS ICD-9 diagnosis codes

- 238.72, 238.73, 238.74, 238.75 (myelodysplastic syndrome)

AND

CPT E/M service codes

- 99201, 99202, 99203, 99204, 99205 (office — new patient),
- 99212, 99213, 99214, 99215 (office — established patient),
- 99241, 99242, 99243, 99244, 99245 (outpatient consult)

Quality codes for this measure (at least one of the following for every eligible patient):

CPT II Code descriptors

(Data Collection sheet should be used to determine appropriate combination of codes.)

- **CPT II 4090F:** Patient receiving erythropoietin therapy
- **CPT II 4095F:** Patient not receiving erythropoietin therapy
- **CPT II 3160F:** Documentation of iron stores prior to initiating erythropoietin therapy
- **CPT II 3160F-3P:** Documentation of system reason(s) for not documenting iron stores prior to initiating erythropoietin therapy
- **CPT II 3160F-8P:** Iron stores prior to initiating erythropoietin therapy not documented, reason not otherwise specified

These Physician Performance Measures (Measures) are not clinical guidelines and do not establish a standard of medical care, and have not been tested for all potential applications.

The Measures, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, e.g., use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain. Commercial uses of the Measures require a license agreement between the user and the American Medical Association (AMA), [on behalf of the Physician Consortium for Performance Improvement® (Consortium)] or the American Society of Hematology (ASH). Neither the AMA, ASH, Consortium nor its members shall be responsible for any use of the Measures.

THE MEASURES AND SPECIFICATIONS ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND.

© 2006–7 American Medical Association and American Society of Hematology. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

Limited proprietary coding is contained in the Measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. The AMA, ASH, the Consortium and its members disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT®) or other coding contained in the specifications.

CPT® contained in the Measures specifications is copyright 2006 American Medical Association. LOINC® copyright 2004 Regenstrief Institute, Inc. SNOMED CLINICAL TERMS (SNOMED CT®) copyright 2004 College of American Pathologists (CAP). All Rights Reserved. Use of SNOMED CT® is only authorized within the United States.

PQRI 2007 Measure 68, Effective Date 07/01/2007

© 2006–7 American Medical Association and American Society of Hematology. All rights reserved.

CPT® copyright 2006 American Medical Association